Aptahem (APTA) Status Update summary

Strategic direction and U.S. listing preparations

• Ongoing preparations for a planned U.S. stock exchange listing to better reflect scientific progress and secure financing for a Phase 2 trial.

• Transition to IFRS accounting standards and engagement with a U.S.-qualified auditor to meet institutional investor requirements.

• Collaboration with U.S. legal advisors to address regulatory and structural requirements for the listing.

Recent initiatives to attract U.S. investors

• Application to the FDA's PreCheck Program to streamline pharmaceutical manufacturing inspections.

• Filing of a provisional U.S. patent to broaden the IP portfolio and increase investor interest.

• Application to the FDA's CNPV Pilot Program, aiming to significantly shorten regulatory review timelines.

Communication and stakeholder engagement

• Announcement of a webinar on September 22 to provide updates on strategic direction and U.S. listing preparations.

• CEO highlights the necessity of a U.S. listing to attract international life science investors and advance clinical trials.

• Webinar will cover the benefits of FDA programs, IP strategy, and concrete steps toward the U.S. listing.